nach oben

The journal of nutrition, health & aging

Erschienen in:

19.03.2018

Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats

verfasst von: Weiying Ren, Jiayu Wu, Li Li, Y. Lu, Y. Shao, Y. Qi, B. Xu, Y. He, Yu Hu

Erschienen in: The journal of nutrition, health & aging | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Glucagon-like peptide-2 (GLP-2) plays a major role in repairing impaired intestinal mucosa, but its mechanism in the improvement of intestinal barrier function during the aging process remains unclear. In this study, 26-month-old male Sprague-Dawley rats were randomized to control group and GLP-2 group treated with a dose of 250 μg•kg-1•d-1 by intraperitoneal injection. After 14 days of treatment, intestinal mucosal morphometric changes were observed by light microscopy and transmission electron microscopy (TEM). Small intestinal permeability was evaluated by fluorescein isothiocyanate (FITC)-labeled dextran. The mRNA and protein expression of Zonula Occludens-1 (ZO-1), occludin, claudin-1 and the GLP-2 receptor (GLP-2R) were detected by Real-time PCR and Western blot. Our results showed that GLP-2 administration significantly improved the age-related atrophy of intestinal mucosa and villi and increased small intestinal permeability. The mRNA and protein expression of ZO-1and occludin in ileum were up regulated in the GLP-2-treated old rats. In addition, the serum GLP-2 levels were negatively correlated with small intestinal permeability measured by FITC-dextran levels (r=-0.610, P<0.01). Taking all these data together, it is concluded that GLP-2 improved small intestinal epithelial barrier function in aged rats mainly by facilitating intestinal mucosa growth, alleviating the increased small intestinal permeability and increasing ZO-1 and occludin expression. Our observations provide evidence for the clinical significance of GLP-2 in preventing the intestinal epithelial barrier dysfunction during aging.

Man AL, Gicheva N, Nicoletti C. The impact of ageing on the intestinal epithelial barrier and immune system. Cell Immunol 2014; 289: 112–8. https://doi.org/10.1016/j.cellimm.2014.04.001CrossRefPubMed

Nicoletti C. Age-associated changes of the intestinal epithelial barrier: local and systemic implications. Expert Rev Gastroenterol Hepatol 2015; 9: 1467–9. http://dx.doi.org/10.1586/17474124.2015.1092872CrossRefPubMed

Hollander D, Tarnawski H. Aging-associated increase in intestinal absorption of macromolecules. Gerontology 1985; 31:133–7.CrossRefPubMed

Katz D, Hollander D, Said HM, Dadufalza V. Aging-associated increase in intestinal permeability to polyethylene glycol 900. Dig Dis Sci 1987; 32: 285–8.CrossRefPubMed

Tran L, Greenwood-Van Meerveld B. Age-Associated Remodeling of the Intestinal Epithelial Barrier. J Gerontol A Biol Sci Med Sci 2013; 68:1045–56. https://doi.org/10.1093/gerona/glt106CrossRefPubMedPubMedCentral

Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y. The inflammatory status of the elderly: the intestinal contribution. Mutat Res 2010; 690: 50–6. https://doi.org/10.1016/j.mrfmmm.2009.07.011CrossRefPubMed

Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003; 9:143–51.CrossRefPubMed

Franceschi C and Campisi J. Chronic inflammation (inflammageing) and its potential contribution to age-associated diseases. J Gerontol A Biol Med Sci 2014; 69 Suppl1: S4–9. https://doi.org/10.1093/gerona/glu057CrossRef

Gong J, Hu M, Huang Z, Fang K, Wang D, Chen Q, et al. Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. Front Pharmacol 2017; 8: 42. https://doi.org/10.3389/fphar.2017.00042CrossRefPubMedPubMedCentral

10.

Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol 2015; 21: 10609–20. https://doi.org/10.3748/wjg.v21.i37.10609CrossRefPubMedPubMedCentral

11.

Ren WY, Wu KF, Li X, Luo M, Liu HC, Zhang SC, et al. Age-related changes in small intestinal mucosa epithelium architecture and epithelial tight junction in rat models. Aging Clin Exp Res 2014; 26(2):183–91. https://doi.org/10.1007/s40520-013-0148-0CrossRefPubMed

12.

Drucker DJ, Erlich P, Asa S L, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93(15): 7911–6.CrossRefPubMedPubMedCentral

13.

Litvak DA, Hellmich MR, Evers BM, Banker NA, Townsend CM Jr. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J Gastrointest Surg 1998; 2(2):146–50.CrossRefPubMed

14.

Chen X, Zhao HX, Fu XS, Li CP, Zhong XL. Glucagonlike peptide 2 protects intestinal barrier in severe acute pancreatitis through regulating intestinal epithelial cell proliferation and apoptosis. Pancreas 2012; 41(7): 1080–5. https://doi. org/10.1097/MPA.0b013e31824966b0CrossRefPubMed

15.

Austin K, Markovic MA, Brubaker PL. Current and potential therapeutic targets of glucagonlike peptide-2. Curr Opin in Pharmacol 2016; 31:13–8. https://doi.org/10.1016/j.coph.2016.08.008CrossRef

16.

Wu J, Qi KK, Xu ZW. Porcine glucagon-like peptide-2 microspheres ameliorate inflammation in lipopolysaccharide-challenged weaning piglets. J Anim Sci 2016; 94(12):5286–94. https://doi.org/10.2527/jas.2016-1007CrossRefPubMed

17.

Nakame K, Kaji T, Mukai M, Shinyama S, Matsufuji H. The protective and anti-inflammatory effects of glucagon-likepeptide-2 in an experimental rat model of necrotizing enterocolitis. Peptides 2016; 75: 1–7. https://doi.org/10.1016/j.peptides.2015.07.025CrossRefPubMed

18.

Moore SA, Nighot P, Reyes C, Rawat M, McKee J, Lemon D, et al. Intestinal barrier dysfunction in human necrotizing enterocolitis. J Pediatr Surg 2016; 51(12):1907–13. http://dx.doi.org/10.1016/j.jpedsurg.2016.09.011CrossRefPubMedPubMedCentral

19.

Galipeau HJ, Verdu EF. The complex task of measuring intestinal permeability in basic and clinical science. Neurogastroenterol Motil 2016; 28(7):957–65. DOI: 10.1111/nmo.12871CrossRefPubMed

20.

Valensinin L, Ramminger S, Haas V, Postrach E, Werich M, Fischer A, et al. Small intestine permeability in older adults. Physiol Rep 2014; 2(4): e00281. DOI: 10.14814/phy2.281CrossRef

21.

Man AL, Bertelli E, Rentini S, Regoli M, Briars G, Marini M, et al. Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin Sci(Lond) 2015; 129(7): 515–27. DOI: 10.1042/CS20150046CrossRef

22.

Mullin JM, Valenzano MC, Verrecchio JJ, Kothari R. Age-and diet-related increase in transepithelial colon permeability of Fischer 344 rats. Dig Dis Sci 2002; 47(10):2262–70.CrossRefPubMed

23.

Ma TY, Hollander D, Dadufalza V, Krugliak P. Effect of aging and caloric restriction on intestinal permeability. Exp Gerontol 1992; 27(3):321–33.CrossRefPubMed

24.

Chen YM, Zhang JS, Duan XL. Changes of microvascular architecture, ultrastructure and permeability of rat jejunal villi at different ages. World J Gastroenterol 2003; 9(4):795–9.CrossRefPubMedPubMedCentral

25.

Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84(3):282–91.CrossRefPubMed

26.

Meier J, Sturm A. The intestinal epithelial barrier: does it become impaired with age? Dig Dis 2009; 27(3):240–5. https://doi.org/10.1159/000228556CrossRefPubMed

27.

Mabbott, NA, Kobayashi A, Sehgal A, Bradford BM, Pattison M, Donaldson DS. Aging and the mucosal immune system in the intestine. Biogerontology 2015; 16(2): 133–45. DOI:10.1007/s10522-014-9498-zCrossRefPubMed

28.

Baldassano S, Amato A. GLP-2: What do we know? What are we going to discover? Regul Pept 2014; 194-195:6–10. https://doi.org/10.1016/j.regpep.2014.09.002CrossRefPubMed

29.

Cameron HL, Perdue MH. Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 2005; 314(1): 214–20. https://doi.org/10.1124/jpet.105.085373CrossRefPubMed

30.

Zhang W, Zhu W, Zhang J, Li N, Li J. Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery 2008; 28(4):285–90. DOI: 10.1002/micr.20491CrossRefPubMed

31.

Teshima CW, Meddings JB. The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep 2008; 10(5):443–9.CrossRefPubMed

32.

Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119(3): 744–55.CrossRefPubMed

33.

Pedersen J, Pedersen NB, Brix SW, Grunddal KV, Rosenkilde MM, Hartmann B, et al. The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. Peptides 2015; 67:20–8. https://doi.org/10.1016/j. peptides.2015.02.007CrossRefPubMed

34.

Rowland KJ, Trivedi S, Lee D, Wan K, Kulkarni RN, Holzenberger M, et al. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulinlike growth factor-1-receptor deletion. Gastroenterology 2011; 141(6): 2166–75. http://dx.doi.org/10.1053/j.gastro.2011.09.014CrossRefPubMed

35.

Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol 2014; 76:561–83. https://doi.org/10.1146/ annurev-physiol-021113-170317CrossRefPubMed

36.

Rowland KJ, Brubaker PL. The «cryptic» mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 2011; 301(1): G1–8. DOI: 10.1152/ajpgi.00039.2011CrossRefPubMed

37.

Lei Q, Bi J, Wang X, Jiang T, Wu C, Tian F, et al. GLP-2 Prevents Intestinal Mucosal Atrophy and Improves Tissue Antioxidant Capacity in a Mouse Model of Total Parenteral Nutrition. Nutrients 2016; 8: 33. DOI: 10.3390/nu8010033CrossRefPubMedCentral

38.

Yu C, Jia G, Deng QH, Zhao H, Chen X, Liu G, et al. The effects of glucagonlike peptide-2 on the tight junction and barrier function in IPEC-J2 cells through phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling pathway. Asian-Australas J Anim Sci 2016; 29(5): 731–8. https://doi. org/10.5713/ajas.15.0415CrossRefPubMed

39.

Qi KK, Sun YQ, Wan J, Deng B, Men XM, Wu J, et al. Effect of porcine glucagonlike peptides-2 on tight junction in GLP-2R + IPEC-J2 cell through the PI 3 k/Akt/mTOR/p70 S6K signalling pathway. J Animl Physiol Anim Nutr (Berl) 2017; doi: 10.1111/jpn.12644.

40.

Moran GW, O’Neill C, McLaughlin JT. GLP-2 enhances barrier formation and attenuates TNFa-induced changes in a Caco-2 cell model of the intestinal barrier. Regul Pept 2012; 178(1-3):95–101. https://doi.org/10.1016/j.regpep.2012.07.002CrossRefPubMed

41.

Raffort J, Lareyre F, Massalou D, Fénichel P, Panaia-Ferrari P, Chinetti G. Insights on glicentin, a promising peptide of the proglucagon family. Biochem Med 2017; 27(2):308–324. https://doi.org/10.11613/BM.2017.034CrossRef

Titel: Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats
verfasst von: Weiying Ren
Jiayu Wu
Li Li
Y. Lu
Y. Shao
Y. Qi
B. Xu
Y. He
Yu Hu
Publikationsdatum: 19.03.2018
Verlag: Springer Paris
Erschienen in: The journal of nutrition, health & aging / Ausgabe 6/2018
Print ISSN: 1279-7707
Elektronische ISSN: 1760-4788
DOI: https://doi.org/10.1007/s12603-018-1022-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Nonpharmacological Treatment of Cognitive Impairment

Longitudinal Analysis of Outpatient Physician Visits in the Oldest Old: Results of the Agequalide Prospective Cohort Study

Rethinking the Staff-Quality Relationship in Nursing Homes

Interventions against disability in frail older adults: Lessons learned from clinical trials

Links Between Atherosclerosis and Osteoporosis in Middle Aged and Elderly Men